|
|
Article: Amarin Corporation Announces Results of Gene Variant Data Analysis From Initial Miraxion(TM) Phase III Clinical Trial.
- Article from:
- PR Newswire
- Article date:
- August 24, 2004
CopyrightCOPYRIGHT 2004 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Analysis Identifies Characteristics of Huntington's Disease Patients Responsive to Miraxion(TM)
Amarin Corporation plc (NASDAQSC: AMRN) today announced the results of a gene variant data analysis from the initial Phase III clinical trial for Miraxion(TM) (formerly referred to as LAX-101) in Huntington's disease. The analysis identifies a group of patients with a specific gene variant that experienced a significant response to Miraxion(TM). The initial twelve month, phase III multi-center, double blind, randomized placebo controlled study of Miraxion(TM) was conducted in 2002 by Laxdale Limited ("Laxdale") with 135 enrolled patients with Huntington's disease at ...